X

Get our occasional Market Report emails

sent straight to your inbox

There’s no charge for this.

Getting latest data loading
X

Request a Call to Trade

In addition to the daily Research emails, I would also like to receive the Accendo Markets Weekly Newsletter and occasional Market Report emails highlighting various trading opportunities.
When you enter your telephone number, we may call or message you occasionally with trading opportunities. You can opt out at any time
Home / Momentum / Hikma Pharmaceuticals PLC (HIK.L) 03-04-20

This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.

Hikma Pharmaceuticals PLC (HIK.L) 03-04-20

Will shares in Hikma Pharmaceuticals PLC (HIK.L) continue to rally, setting new recent highs?

  • Now trading at 2198p (at time of writing), the share price performance has been very strong.
  • Will it end, or is this trend your friend?
  • Could this be the ideal opportunity for momentum traders?
  • Whilst momentum has been strong, traders should remember that past performance is not necessarily an indication of the future.
  • Technical traders should consider of new events, which can influence price action. Check our website and news outlets for updates.
  • Shares -0% from 12-month highs; +39% from 12 month lows.

Latest News

09:50:  Citigroup reiterates its buy rating on Hikma Pharmaceuticals (HIK) and increased the target price to 2500p (from 2150p).

02 Apr:  Peel Hunt has upgraded its rating on Hikma Pharmaceuticals (HIK) to buy (from hold) and increased the target price to 2380p (from 1990p).

31 Mar: Hikma Pharmaceuticals announced that a U.S. ruling that patents covering Amarin’s heart drug were not valid, meaning the company can sell generic versions.

12 Mar:  Jefferies International reiterates its buy rating on Hikma Pharmaceuticals (HIK) and increased the target price to 2390p (from 2300p).

10 Mar:  Citigroup has upgraded its rating on Hikma Pharmaceuticals (HIK) to buy (from neutral) and increased the target price to 2150p (from 1980p).

02 Mar:  Barclays Capital reiterates its equal weight rating on Hikma Pharmaceuticals (HIK) and increased the target price to 1950p (from 1900p).

27 Feb:  Hikma Pharmaceuticals posted an increase in profits as cost reductions and better revenues supported performance.

Source: Bloomberg, Reuters, Alpha Terminal, FT, DJ Newswires

Click to enlarge

This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.


Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance.

Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.

About Us

Accendo Markets is an award-winning provider of CFD and spread betting trading services. We provide an execution-only service.

Get in Touch

Quick Links

Telephone calls and online chat conversations may be monitored and recorded for regulatory and training purposes.

* We provide these as underlying assets to CFDs and Spreadbets.

To view our policies and terms, please click here

This website is not intended for or directed at residents of the United States or any country outside the UK. It is not intended for use by or distribution to any person in any jurisdiction or country where its use or distribution would contravene any regulation or local law.
Prices on this page are delayed.

Like many websites, we use cookies for statistical purposes and to acquire information on general internet use. This helps ensure that you get the full benefit of our services, and enhances your browsing experience . For more details on the cookies we use, view our privacy policy under the heading 'How We Use Cookies'. By using this website, we'll assume that you're happy to receive all cookies from Accendo Markets.
Removing cookies may impede the operation of some parts of this website. For general information about cookies and how to remove them, please click here 

Accendo Markets Ltd - Highstone House, 165 High Street, Barnet EN5 5SU (UK) Telephone: 020 3051 7461 - Accendo Markets Ltd. is Authorised and Regulated by the Financial Conduct Authority (FCA) No. 475285. Accendo Markets Ltd. Registered in England and Wales No. 6417051. © Copyright Accendo Markets Ltd 2015. All rights reserved.
.